A genetically engineered drug known as BL22 has sent a type of cancer called hairy cell leukemia into full remission in 11 of 16 patients, a study shows. Two other patients experienced partial remission.
The findings, reported in the July 26 New England Journal of Medicine, suggest that BL22 may become a treatment for this type of leukemia.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.